The partnership integrates Leveragen’s Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight Bio.

Immune cells called regulatory T cells have long been known for their role in countering inflammation. In the setting of ...

He is best known as the lead scientist of the group that first cloned the genes of the human T cell antigen receptor, a discovery that provided essential insights into the molecular basis of ...

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

Key findings include modulation of: FoxP3 T regulatory cells (Tregs) CD4+ and CD8+ central memory T cells CD14 ... Tiziana’s lead candidate, intranasal foralumab, which is the only fully human ...

(“Candid”), a clinical stage biotechnology company positioned to lead the development of T cell engagers for autoimmune ... therapeutic antibodies against human diseases with unmet clinical ...

Armed with $120 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ... previously led portfolio development at Human Immunology Biosciences ...